Niosomally encapsulated silver sulfadiazine gel for burn treatment

Abstract

Silver sulfadiazine (SSD) is the antibacterial of choice for the treatment of burn. The current marketed formulation of SSD is 1% w/w water soluble cream, which requires frequent applications, which is very painful to patients. Niosomes were prepared by a thin film hydration method. The in vitro antimicrobial efficiency of niosomal SSD (18 ± 0.5 mm) was as good as that of marketed cream (17 ± 0.5 mm) against Staphylococcus aureus even when used in half the concentration (0.5%) of marketed cream (1%). Further SSD (0.5% w/w) niosomal gel was prepared using 1.6% carbopol 934. It was evident through in vitro permeation studies that SSD release was considerably retarded from both niosomes and niosomal gel in comparison with marketed cream thereby decreasing the dosing frequency. In-vivo study demonstrated that a niosomal gel containing 0.5% w/w SSD was more effective in burn wound healing compared to 1% w/w marketed cream even when applied once a day.

• Antimicrobial study
• burn model
• niosomal gel
• silver sulfadiazine

Acknowledgements

The authors are thankful to Ajanta Pharma Limited, Mumbai, India, for a gift sample of silver sulfadiazine. The authors also thank S. D. Fine Chemicals Ltd., Mumbai, India, for providing gift samples of the excipients. The authors wish to thank Dr. L. H. Hiranandani College of Pharmacy, Ulhasnagar, India, for providing the animals.

Declaration of interest

All authors hereby declare that this is an original, self funded research work performed using the facilities available in our laboratories and authors do not have any financial, personal, employment related, stock ownership related, honoraria or paid expert testimony related, patent related, grants or other funding related or any other conflict with any people, organisations or consultancies that could inappropriately influence (bias) our work. The authors report no declarations of interest.